This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Carboplatin | |
|---|---|
| Drug name | Carboplatin |
| Routes of administration | Intravenous |
| Class | Antineoplastic agent; alkylating-like agent |
| Legal status | Prescription-only |
Carboplatin Carboplatin is a platinum-based chemotherapeutic agent used in oncology. Developed as a second-generation derivative of an earlier platinum compound, it is employed in multiple cancer regimens and combined with surgery, radiation, and targeted therapies. Clinical use spans gynecologic, thoracic, and genitourinary malignancies managed in multidisciplinary centers.
Carboplatin is indicated for treatment of epithelial ovarian cancer, small cell lung cancer, non-small cell lung cancer, head and neck cancers, and testicular cancer as part of combination regimens employed in hospitals such as Royal Marsden Hospital, Memorial Sloan Kettering Cancer Center, and Mayo Clinic. It is used in frontline adjuvant settings alongside agents associated with protocols from National Comprehensive Cancer Network, European Society for Medical Oncology, and American Society of Clinical Oncology guidelines. In recurrent disease, carboplatin features in platinum-sensitive relapse protocols developed through trials by groups like Gynecologic Oncology Group and European Organisation for Research and Treatment of Cancer. Combination strategies may pair it with taxanes influenced by research at institutions including Dana-Farber Cancer Institute and Johns Hopkins Hospital.
Carboplatin exerts cytotoxicity via formation of DNA crosslinks, a mechanism elucidated in foundational work at laboratories connected to Max Planck Society and universities such as University of Oxford and Harvard University. Crosslinks trigger pathways involving sensors and effectors characterized at institutes like Institut Pasteur, Cold Spring Harbor Laboratory, and Broad Institute. Cellular responses engaging nucleotide excision repair, homologous recombination mediated by proteins studied at Massachusetts Institute of Technology, and apoptosis programs defined in research from Salk Institute determine sensitivity to platinum drugs. Resistance mechanisms mapped by consortia including Wellcome Trust contributors implicate efflux transporters investigated at Stanford University and detoxification systems detailed at Karolinska Institutet.
Pharmacokinetic characterization emerged from clinical pharmacology units at centers like UCLA Medical Center and Imperial College London. Carboplatin displays renal elimination with clearance parameters informed by equations adopted by National Kidney Foundation and studies from Cleveland Clinic. Pharmacokinetic modeling efforts drawing on work at ETH Zurich and McGill University have guided dosing calculations. Protein binding and distribution studies reported in journals affiliated with Oxford University Press and Nature Publishing Group informed understanding of volume of distribution relevant to patients managed at Guy's and St Thomas' NHS Foundation Trust and Karolinska University Hospital.
Dose calculation commonly uses the Calvert formula developed in research associated with University College Hospital, London and applied in protocols disseminated by European Medicines Agency and Food and Drug Administration. Administration occurs intravenously in oncology suites run by organizations like Cancer Research UK and American Cancer Society affiliates, with regimens tailored according to performance status metrics standardized by Eastern Cooperative Oncology Group and World Health Organization. Combination regimens mirror trials from cooperative groups including SWOG and Children's Oncology Group when used in specific indications and clinical trials overseen by bodies such as National Institutes of Health.
Myelosuppression, particularly thrombocytopenia, and hematologic toxicity were characterized in early clinical trials at centers like Memorial Sloan Kettering Cancer Center and Royal Marsden Hospital. Nephrotoxicity profiles informed by comparative studies at University of Tokyo and Seoul National University Hospital differ from those of its predecessor compound studied at Institut Curie. Ototoxicity, gastrointestinal effects, and hypersensitivity reactions have been reported in pharmacovigilance databases managed by European Medicines Agency and Medicines and Healthcare products Regulatory Agency. Management strategies reference supportive care standards promulgated by American Society of Hematology and transfusion guidelines from British Blood Transfusion Society.
Contraindications and precautions follow assessments used by regulatory agencies like Food and Drug Administration and European Medicines Agency and are applied in clinical practice at tertiary centers such as Johns Hopkins Hospital and Karolinska University Hospital. Renal impairment considerations draw on guidance from National Kidney Foundation and dosing adjustments reflect creatinine clearance estimations popularized by research from Mayo Clinic. Pregnancy-related teratogenicity warnings align with recommendations from American College of Obstetricians and Gynecologists and oncology pregnancy registries maintained by EORTC. Monitoring protocols reference laboratory standards by College of American Pathologists and adverse event grading by Common Terminology Criteria for Adverse Events.
Carboplatin was developed as a less nephrotoxic alternative to an antecedent platinum compound discovered in studies at University of Oxford and advanced through clinical development involving investigators at Royal Marsden Hospital, Institute of Cancer Research, and pharmaceutical entities such as companies traced through collaborations with GlaxoSmithKline and other industry partners. Early randomized trials that established its role were conducted by cooperative groups including Gynecologic Oncology Group and North Central Cancer Treatment Group, with pivotal data published in journals associated with The Lancet and New England Journal of Medicine. Its adoption into practice was influenced by health technology assessments from agencies like National Institute for Health and Care Excellence and reimbursement decisions by organizations such as Centers for Medicare & Medicaid Services.
Category:Antineoplastic agents